Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Tactogen Inc. currently maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. Prosecution is limited to 1 distinct examiner and 1 distinct art unit, reflecting a highly specific area of interest. MCDOWELL, BRIAN E is the busiest examiner, currently overseeing the 1 pending office action. With only 1 distinct examiner and 1 distinct art unit involved, the prosecution profile is streamlined, allowing for a direct and focused engagement with the patent office's biotechnology division.
The single pending office action represents the entirety of the company's current active engagement with the patent office. This focused approach allows for a dedicated response to the examiner's requirements without the distraction of multiple competing deadlines. Because the matter is handled by the assigned examiner, MCDOWELL, BRIAN E, the applicant can develop a consistent rapport and understanding of the examiner's specific concerns. This can often lead to a more efficient path toward allowance than in more complex portfolios.
The presence of a single art unit suggests that the technology is being reviewed by a specialized group with deep expertise in a particular niche of Biotechnology & Pharmaceuticals. Practitioners should leverage this by providing highly technical and precise responses to the 1 pending office action. The company's strategy is currently centered on this single matter, making its resolution a high priority for the overall intellectual property portfolio in this technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18653750 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | MCDOWELL, BRIAN E | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18653750 | INDOLIZINE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | MCDOWELL, BRIAN E | 1624 | §102 | Non-Final OA | — | Pending | May 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTactogen Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brian E Mcdowell has the most, with 1 of Tactogen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
